CA-BLOOMREACH
Bloomreach, the platform fueling limitless e-commerce personalization, today announced the acquisition of Radiance Commerce, a revolutionary, enterprise-grade conversational commerce platform powered by the latest in generative AI. Using large language models (LLMs), Radiance guides customers on their shopping journey through expertise-based selling, product search, recommendations, and exploration. In joining Bloomreach, the Radiance team brings deep, technical expertise in AI and conversational commerce to further propel Bloomreach’s innovation in AI for e-commerce.
The expertise offered by Radiance will specifically fuel the advancement of Bloomreach Clarity™, a conversational shopping product offering human-like product expertise at scale, announced at Bloomreach’s 2023 Edge Summit. Already in active testing phases with a number of businesses, Clarity will be further optimized with the groundbreaking conversational technology developed by Radiance.
“Bloomreach is fully invested in an AI-driven future for e-commerce, and Radiance Commerce is critical in helping us bring that future to life,” said Raj De Datta, co-founder and CEO, Bloomreach. “We have the most robust commerce dataset out there and commerce-specific AI connected to every channel in the shopping journey. Now, we take that unmatched foothold in e-commerce a step further, advancing our conversational capabilities and moving even faster to make Bloomreach Clarity available to businesses around the world. We couldn’t be more excited to bring Radiance’s unique expertise to Bloomreach.”
Radiance Commerce was founded in 2017 by Vikas Jha, who previously served as a Director of Engineering at Google. Joined by a team of product and engineering experts, Jha spent years on the development of AI that would enable shopping by conversing — helping customers access advice and product expertise previously confined to the in-store experience. The potential of that technology was fully unleashed in 2022, as unprecedented developments in generative AI and LLMs opened up entirely new conversational possibilities.
“The visions of Radiance Commerce and Bloomreach are perfectly aligned, and we’re pleased to join forces as we embark on this journey toward the future of shopping together,” said Vikas Jha. “Bloomreach is a big player in the world of e-commerce technology, serving an incredible customer base. We are a team of product builders at heart, with years of conversational AI expertise. In coming together, we can take a truly incredible conversational shopping product and deliver it quickly to the growing market eagerly awaiting it.”
About Bloomreach
Bloomreach personalizes the e-commerce experience. Its data engine unifies real-time customer and product data so businesses understand what customers really want. By connecting that understanding to every channel, the e-commerce experience becomes limitless — reflecting a changing customer as they shop. Amplified by the speed and scale of Loomi, Bloomreach's AI for e-commerce, this creates endless new paths to purchase, greater profitability, and fast business growth. Bloomreach products include: Engagement, a marketing automation platform; Discovery, an e-commerce search solution; Content, a headless CMS; and Clarity, AI-powered conversational shopping. The company has multiple AI patents and serves 1,400+ global brands including: Williams-Sonoma, Bosch, Puma, and Marks & Spencer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123660710/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release
New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release
First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release
Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont
TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 12:00:00 CET | Press release
TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors
Celonis Unveils Platform Innovations to Power the AI-Driven, Composable Enterprise4.11.2025 11:00:00 CET | Press release
Celonis, a global leader in Process Intelligence, today at Celosphere 2025 announced major platform innovations that power enterprise AI to reinvent and continuously improve business operations. Daniel Brown, Chief Product Officer at Celonis, emphasized the need for a structured approach to agentic AI. “To truly operationalize AI, you need to identify the right use cases, redesign your business processes, and orchestrate the agents alongside your people and existing systems," Brown said. "Our enhanced capabilities empower our customers and their partners to build AI solutions that lift their operations to unprecedented levels of efficiency and agility.” The Celonis Process Intelligence Platform extracts raw data from systems, applications and devices within and across enterprises. It enriches this data with customers’ unique business context to create a living digital twin of operations—the Process Intelligence Graph. On top of the Graph, the Process Intelligence Platform provides the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom